New Risk • Jul 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Revenue is less than US$5m (JP¥410m revenue, or US$2.5m). Market cap is less than US$100m (€38.5m market cap, or US$44.0m). Reported Earnings • May 20
First quarter 2026 earnings released: JP¥1.14 loss per share (vs JP¥1.34 loss in 1Q 2025) First quarter 2026 results: JP¥1.14 loss per share. Revenue: JP¥6.00m (down 76% from 1Q 2025). Net loss: JP¥307.0m (loss widened 5.1% from 1Q 2025). Tillkännagivande • Feb 13
Solasia Pharma K.K., Annual General Meeting, Mar 25, 2026 Solasia Pharma K.K., Annual General Meeting, Mar 25, 2026. Tillkännagivande • Dec 18
Solasia Pharma K.K. to Report Fiscal Year 2025 Results on Feb 13, 2026 Solasia Pharma K.K. announced that they will report fiscal year 2025 results on Feb 13, 2026 Tillkännagivande • Apr 10
Solasia Pharma K.K. announced that it has received ¥2.176 million in funding from Macquarie Group Limited On April 9, 2025, Solasia Pharma K.K. closed the transaction. Tillkännagivande • Mar 24
Solasia Pharma K.K. announced that it expects to receive ¥2.176 million in funding from Macquarie Group Limited Solasia Pharma K.K. announced a private placement to issue 544,000 Series 15 warrant at an issue price of ¥4 per warrant for gross proceeds of ¥2,176,000 on March 24, 2025. The transaction will include participation from new investor Macquarie Bank Limited. The transaction has been approved by shareholders, expected to close on April 9, 2025. The funding amount of the transaction is ¥2,069,376,000 (estimated amount of proceeds excluding costs: ¥2,049,376,000) and exercise price is ¥38. Tillkännagivande • Feb 12
Solasia Pharma K.K., Annual General Meeting, Mar 26, 2025 Solasia Pharma K.K., Annual General Meeting, Mar 26, 2025. Tillkännagivande • Jan 06
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024 Solasia Pharma K.K. revised consolidated earnings guidance for the fiscal year ending December 31, 2024. For the year, the company expects revenue to be JPY 300 million, operating loss to be JPY 1,050 million, loss attributable to owners of parent JPY 1,050 million or basic loss per share to be JPY 5.28 against pervious guidance of revenue to be JPY 160 million, operating loss to be JPY 1,150 million, loss attributable to owners of parent JPY 1,150 million or basic loss per share to be JPY 5.79. Tillkännagivande • Jan 03
Solasia Pharma K.K. to Report Fiscal Year 2024 Results on Feb 14, 2025 Solasia Pharma K.K. announced that they will report fiscal year 2024 results on Feb 14, 2025 Reported Earnings • Aug 19
Second quarter 2024 earnings released: JP¥1.58 loss per share (vs JP¥1.17 loss in 2Q 2023) Second quarter 2024 results: JP¥1.58 loss per share (further deteriorated from JP¥1.17 loss in 2Q 2023). Net loss: JP¥301.0m (loss widened 54% from 2Q 2023). Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. New Risk • Jul 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (JP¥408m revenue, or US$2.6m). Market cap is less than US$100m (€50.0m market cap, or US$54.3m). Reported Earnings • May 21
First quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥1.44 loss in 1Q 2023) First quarter 2024 results: JP¥1.78 loss per share (further deteriorated from JP¥1.44 loss in 1Q 2023). Revenue: JP¥11.0m (down 95% from 1Q 2023). Net loss: JP¥310.0m (loss widened 29% from 1Q 2023). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Tillkännagivande • May 16
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024 Solasia Pharma K.K. provided consolidated earnings forecasts for the fiscal year ending December 31, 2024. For the year, the company expects revenue to be in the range of JPY 1,250 million to JPY 1,500 million, operating loss to be in the range of JPY 800 million to JPY 550 million, loss to be in the range of JPY 800 million to JPY 550 million, loss attributable to owners of parent to be in the range of JPY 800 million to JPY 550 million and basic loss per share to be in the range of JPY 4.39 to JPY 3.02. Reported Earnings • Mar 28
Full year 2023 earnings released: JP¥6.61 loss per share (vs JP¥16.77 loss in FY 2022) Full year 2023 results: JP¥6.61 loss per share (improved from JP¥16.77 loss in FY 2022). Revenue: JP¥617.0m (down 44% from FY 2022). Net loss: JP¥1.11b (loss narrowed 56% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. New Risk • Mar 25
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: JP¥1.1b Forecast net loss in 1 year: JP¥538m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (JP¥538m net loss next year). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Revenue is less than US$5m (JP¥617m revenue, or US$4.1m). Market cap is less than US$100m (€34.0m market cap, or US$36.8m). Tillkännagivande • Mar 05
Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited On March 4, 2024, Solasia Pharma K.K. closed the transaction. Breakeven Date Change • Mar 04
Forecast breakeven date pushed back to 2026 The analyst covering Solasia Pharma K.K previously expected the company to break even in 2025. New forecast suggests the company will make a profit of JP¥196.0m in 2026. Average annual earnings growth of 65% is required to achieve expected profit on schedule. Reported Earnings • Feb 18
Full year 2023 earnings released: JP¥6.61 loss per share (vs JP¥16.77 loss in FY 2022) Full year 2023 results: JP¥6.61 loss per share (improved from JP¥16.77 loss in FY 2022). Revenue: JP¥617.0m (down 44% from FY 2022). Net loss: JP¥1.11b (loss narrowed 56% from FY 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 16
Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited Solasia Pharma K.K. announced a private placement of 40 1% series 3 unsecured non-convertible bonds at a price of ¥12,500,000 per bond for the gross proceeds of ¥500,000,000 and 433,000 14th stock acquisition rights at a price of ¥10 per warrant for the gross proceeds of ¥4,330,000 on February 15, 2024. The bonds carry a coupon rate of 1% per annum and is expected to close on March 4, 2024. The transaction has been approved by the shareholders of the company. The company expects estimated net proceeds ¥1,693,030,000 inclusive of amount raised by issuing stock acquisition rights ¥4,330,000 and amount raised by exercising stock acquisition rights ¥1,688,700,000. The bonds will mature on March 3, 2027 and warrant exercise price is ¥39. Tillkännagivande • Feb 14
Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024 Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024. New Risk • Jan 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (€48.7m market cap, or US$53.0m). New Risk • Jan 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (€44.4m market cap, or US$48.6m). Tillkännagivande • Dec 28
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 Solasia Pharma K.K. revised consolidated earnings guidance for the fiscal year ending December 31, 2023. For the year, the company now expects revenue of JPY 620 million, operating loss of JPY 1,150 million, loss attributable to owners of parent of JPY 1,150 million and basic loss per share of JPY 6.62 against previous forecast of revenue between JPY 1,000 million to JPY 1,800 million, operating loss between JPY 1,150 million to JPY 350 million, loss attributable to owners of parent between JPY 1,150 million to JPY 350 million and basic loss per share between JPY 6.85 to JPY 2.08. New Risk • Dec 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-JP¥1.2b). Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (€55.9m market cap, or US$60.6m). Reported Earnings • Nov 17
Third quarter 2023 earnings released: JP¥1.97 loss per share (vs JP¥4.95 loss in 3Q 2022) Third quarter 2023 results: JP¥1.97 loss per share (improved from JP¥4.95 loss in 3Q 2022). Revenue: JP¥73.0m (down 75% from 3Q 2022). Net loss: JP¥331.0m (loss narrowed 59% from 3Q 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 13
Second quarter 2023 earnings released: JP¥1.17 loss per share (vs JP¥4.38 loss in 2Q 2022) Second quarter 2023 results: JP¥1.17 loss per share (improved from JP¥4.38 loss in 2Q 2022). Revenue: JP¥309.0m (up 307% from 2Q 2022). Net loss: JP¥196.0m (loss narrowed 69% from 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 13
Second quarter 2023 earnings released: JP¥1.17 loss per share (vs JP¥4.38 loss in 2Q 2022) Second quarter 2023 results: JP¥1.17 loss per share (improved from JP¥4.38 loss in 2Q 2022). Revenue: JP¥309.0m (up 307% from 2Q 2022). Net loss: JP¥196.0m (loss narrowed 69% from 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Reported Earnings • May 18
First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥4.61 loss in 1Q 2022) First quarter 2023 results: JP¥1.44 loss per share (improved from JP¥4.61 loss in 1Q 2022). Revenue: JP¥220.0m (up 95% from 1Q 2022). Net loss: JP¥241.0m (loss narrowed 61% from 1Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Auditor Yoshiyuki Yamakawa was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Mar 28
Full year 2022 earnings released: JP¥16.77 loss per share (vs JP¥19.04 loss in FY 2021) Full year 2022 results: JP¥16.77 loss per share. Revenue: JP¥1.09b (up 95% from FY 2021). Net loss: JP¥2.55b (loss widened 2.8% from FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Germany. Reported Earnings • Feb 16
Full year 2022 earnings released: JP¥16.77 loss per share (vs JP¥19.04 loss in FY 2021) Full year 2022 results: JP¥16.77 loss per share. Revenue: JP¥1.09b (up 95% from FY 2021). Net loss: JP¥2.55b (loss widened 2.8% from FY 2021). Tillkännagivande • Feb 14
Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023 Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023. Tillkännagivande • Dec 06
Solasia Pharma K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023 Solasia Pharma K.K. announced that they will report fiscal year 2022 results on Feb 14, 2023 Tillkännagivande • Nov 26
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022 Solasia Pharma K.K. revised consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue of ¥1,150 million, operating loss of ¥2,350 million, loss attributable to owners of parent of ¥2,450 and basic loss per share of ¥14.60 compared to previous guidance of revenue of ¥1,150 million, operating loss of ¥2,150 million, loss attributable to owners of parent of ¥2,250 and basic loss per share of ¥13.41. Reported Earnings • Nov 16
Third quarter 2022 earnings released: JP¥4.95 loss per share (vs JP¥5.46 loss in 3Q 2021) Third quarter 2022 results: JP¥4.95 loss per share. Revenue: JP¥296.0m (up JP¥291.0m from 3Q 2021). Net loss: JP¥802.0m (loss widened 12% from 3Q 2021). Tillkännagivande • Nov 15
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022 Solasia Pharma K.K. revised consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue of ¥1,150 million, operating loss of ¥2,150 million, loss attributable to owners of parent of ¥2,250 and basic loss per share of ¥13.41 compared to previous guidance of revenue in the range of ¥2,300 million to ¥3,800 million, operating loss in the range of ¥1,100 million to operating profit of ¥150 million, loss in the range of ¥1,200 million to profit of ¥50 million, basic loss per share in the range of ¥8.02 to basic earnings per share of ¥0.33. Buying Opportunity • Sep 14
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 31%. The fair value is estimated to be €0.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 299% in 2 years. Earnings is forecast to grow by 78% in the next 2 years. Tillkännagivande • Sep 07
Solasia Announces Summary of SP-04 PledOx Development Status Solasia Pharma K.K. officially announced egarding SP-04 PledOx® development status. The results of the non-clinical study conducted since 2021 at the University of Milan, Italy, using a rat model of Taxane-induced peripheral neuropathy are now available, and have evaluated the results with Egetis Therapeutics AB, the licensor of SP-04 PledOx®, and Professor Cavaletti of the University of Milan, who was responsible for conducting the study. The results of the study suggest that SP-04 PledOx® may have protective effect on Taxane-induced peripheral neuropathy in terms of the evaluation of some of the parameters predefined in the study protocol. On the other hand, other parameters did not show the same results, and the overall interpretation of the study result was complicated and did not confirm a clear protective effect on the onset of Taxane-induced peripheral neuropathy. A new animal study will be planned based on the useful information suggested by this study. Tillkännagivande • Aug 23
Solasia Announces Launch of Darvias in Japan Solasia Pharma K.K. announced that an organoarsenic drug "DARVIAS® Injection 135mg" (SP-02, hereinafter DARVIAS®) has been launched in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co. Ltd. Reported Earnings • Aug 17
Second quarter 2022 earnings released: JP¥4.38 loss per share (vs JP¥5.67 loss in 2Q 2021) Second quarter 2022 results: JP¥4.38 loss per share (up from JP¥5.67 loss in 2Q 2021). Revenue: JP¥76.0m (down 59% from 2Q 2021). Net loss: JP¥632.0m (loss narrowed 14% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Aug 16
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022 Solasia Pharma K.K. provided consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue in the range of ¥2,300 million to ¥3,800 million, operating loss in the range of ¥1,100 million to operating profit of ¥150 million, loss in the range of ¥1,200 million to profit of ¥50 million, basic loss per share in the range of ¥8.02 to basic earnings per share of ¥0.33. Tillkännagivande • Aug 04
Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin) Solasia Pharma K.K. announced results that neither the primary endpoint of Overall Response Rate (ORR) nor the key secondary endpoint in Progression Free Survival (PFS) achieved statistical significance in the multi-center, international Phase III AGENT Study of arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in metastatic colorectal cancer (mCRC). The AGENT Study is the first to evaluate a meaningful alternative to the standard of care for all patients with mCRC since 2004. In the AGENT study, patients with non-resectable mCRC treated with arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab did not experience a statistically significant overall response rate of 10% as compared to patients treated with the standard of care (leucovorin + 5-FU, oxaliplatin and bevacizumab). The AGENT Study will be completed in accordance with regulations and the full data set will be published in order to enable the scientific community to fully take advantage of learnings. Pending results of further analyses, patients remaining on treatment in the experimental arm of the study will be offered to move to the standard of care treatment arm. Tillkännagivande • Jul 16
Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd. On July 14, 2022, Solasia Pharma K.K. closed the transaction. Tillkännagivande • Jun 30
Solasia Pharma K.K. announced that it expects to receive ¥1.02 billion in funding from Nippon Kayaku Co., Ltd. Solasia Pharma K.K. announced that it has entered into capital and business alliance agreement for 12,000,000 shares at issue price of ¥85 per share for gross proceeds of ¥1,020,000,000 on June 28, 2022. The transaction will include participation from new investor, Nippon Kayaku Co., Ltd. for 7.77% stake in the company. The transaction is expected to close on July 14, 2022. Of the total capital increase, ¥510,000,000 will go for capital increase and ¥510,000,000 for capital reserve of the company. The company has incurred ¥30,000,000 for issuance cost receiving net proceeds of ¥990,000,000. The transaction has been approved by the board of directors of the company. Tillkännagivande • Jun 20
Solasia Pharma K.K. Announces an Organoarsenic Drug "Darvias® Injection 135Mg" (Sp-02, Hereinafter Darvias®) Has Been Approved for Relapsed or Refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare Solasia Pharma K.K. officially announced that an organoarsenic drug "DARVIAS® Injection 135mg" (SP-02, hereinafter DARVIAS®) has been approved for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter "PTCL") by the Ministry of Health, Labor and Welfare (MHLW). Solasia filed an NDA with the MHLW in Japan in June 2021. In October 2021, Nippon Kayaku Co. Ltd. (TSE: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) secured a license agreement with DARVIAS® for marketing rights in Japan. DARVIAS®, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors. The proposed mechanism of action of the drug involves the disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways. DARVIAS® is believed to exert an anticancer effect by inducing cell cycle arrest and apoptosis. This approval is based on the result of an Asian Multinational phase II study of SP-02 in patients with relapsed or refractory PTCL, Japan being the first country in the world where it was approved. Reported Earnings • May 16
First quarter 2022 earnings released: JP¥4.61 loss per share (vs JP¥5.22 loss in 1Q 2021) First quarter 2022 results: JP¥4.61 loss per share (up from JP¥5.22 loss in 1Q 2021). Revenue: JP¥113.0m (up 24% from 1Q 2021). Net loss: JP¥615.0m (loss narrowed 6.2% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Mar 04
Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited On March 2, 2022, Solasia Pharma K.K. closed the transaction. The company has issued 2nd unsecured straight bonds for proceeds of ¥500,000,000 in the transaction. The company received aggregate gross proceeds of ¥3,942,890,000 in the transaction. Tillkännagivande • Feb 15
Solasia Pharma K.K. announced that it expects to receive ¥3.44289 billion in funding from Macquarie Group Limited Solasia Pharma K.K. announced issuance of 2nd unsecured corporate bonds and the 13th stock acquisition right on February 14, 2022. The transaction will include participation from Macquarie Group Limited. The total number of stock acquisition rights 33,000,000 at issue price ¥104.33 per stock acquisition rights for gross proceeds of ¥3,442,890,000 on February 14, 2022. There is no maximum strike price. The minimum exercise price of the Stock Acquisition Rights is ¥57, but the number of potential shares is 33,000,000 shares even at the minimum exercise price. The amount raised by exercising stock acquisition rights after incurring expense of ¥20,000,000 is ¥ 3,432,000,000. The exercise period for stock acquisition rights From March 3, 2022 to March 4, 2024. The transaction is expected to close on March 2, 2022. The transaction has been approved by the board of directors. Reported Earnings • Feb 10
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: JP¥19.04 loss per share (up from JP¥35.16 loss in FY 2020). Revenue: JP¥559.0m (up 23% from FY 2020). Net loss: JP¥2.48b (loss narrowed 40% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Feb 10
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022 Solasia Pharma K.K. provided consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects consolidated revenue of ¥2,300 million ~ ¥3,800 million, operating loss of ¥1,100 million ~ operating profit of ¥150 million, net loss attributable to owners of parent of ¥1,200 million ~ net profit attributable to owners of parent of ¥50 million, basic loss per share of ¥8.99 ~ basic earnings per share of ¥0.37. Tillkännagivande • Feb 09
Solasia Pharma K.K., Annual General Meeting, Feb 24, 2022 Solasia Pharma K.K., Annual General Meeting, Feb 24, 2022. Reported Earnings • Nov 11
Third quarter 2021 earnings released: JP¥5.46 loss per share (vs JP¥5.71 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥5.00m (down 89% from 3Q 2020). Net loss: JP¥717.0m (loss widened 7.8% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 13
Second quarter 2021 earnings released: JP¥5.67 loss per share (vs JP¥6.36 loss in 2Q 2020) The company reported a solid second quarter result with improved revenues and control over costs, although losses were not reduced. Second quarter 2021 results: Revenue: JP¥186.0m (up 121% from 2Q 2020). Net loss: JP¥738.0m (flat on 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Jul 01
Solasia Pharma K.K. Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan Solasia Pharma K.K. announced submission of a New Drug Application (NDA) for its new anti-cancer drug darinaparsin (generic name, development code: SP-02) as a treatment for relapsed or refractory peripheral T-cell lymphoma to the Ministry of Health, Labour and Welfare (MHLW). Based on positive results of R&D on darinaparsin, centered primarily on the results of the Asian Multinational Phase 2 Study (study results released in June 2020), Solasia filed an NDA for the drug with the regulatory authority in Japan ahead of anywhere else in the world. Solasia expects to obtain regulatory approval in 2022 and to also launch in the same year. If approved and launched, darinaparsin would be the third drug Solasia successfully developed and brought to market since its founding and is expected to contribute to the treatment of PTCL. Reported Earnings • May 14
First quarter 2021 earnings released: JP¥5.22 loss per share (vs JP¥4.54 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: JP¥91.0m (down 42% from 1Q 2020). Net loss: JP¥656.0m (loss widened 24% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 03
Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: JP¥454.0m (down 65% from FY 2019). Net loss: JP¥4.13b (loss widened 121% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Mar 04
Solasia Pharma K.K. to Report Q1, 2021 Results on May 12, 2021 Solasia Pharma K.K. announced that they will report Q1, 2021 results on May 12, 2021 
